Enanta Pharmaceuticals | ENTA - Capital Y Las Reservas





Capital Y Las Reservas Cambio Fecha
AbbVie USD -3.27B 628M 2025-12
Amgen USD 9.19B 532M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 568.42M 102.37M 2025-12
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Biogen USD 18.65B 394.9M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Immunic USD -6.67M 17.17M 2025-12
Incyte USD 5.62B 455.37M 2026-03
Insmed USD 738.98M 206.6M 2025-12
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
Merck USD 45.88B 6.73B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -127.75M 28.92M 2025-12
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -205.31M 49.56M 2025-12
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03